VTR trades 17.5% below Wall Street's consensus target of $95.86.
Last 12 months price action with 12-month analyst target path
The base valuation assumes VTR achieves its forward estimates and maintains a stable P/E multiple of 130.8x. This scenario reflects the blended consensus of 32 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Ventas, Inc. (VTR) has a Wall Street consensus price target of $95.86, based on estimates from 32 covering analysts. With the stock currently trading at $81.61, this represents a potential upside of +17.5%. The company has a market capitalization of $38.80B.
Analyst price targets range from a low of $88.00 to a high of $110.00, representing a 23% spread in expectations. The median target of $95.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 19 analysts rating the stock as a Buy or Strong Buy,11 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, VTR trades at a trailing P/E of 151.1x and forward P/E of 130.8x. Analysts expect EPS to grow +16.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $52.00, with bear and bull scenarios of $32.76 and $68.51 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
WELLWelltower Inc. | $144.8B | $206.65 | $237.80 | +15.1% | Buy | 71.3x | 34 |
HRHealthcare Realty Trust Incorporated | $6.9B | $19.79 | $21.83 | +10.3% | Hold | — | 30 |
OHIOmega Healthcare Investors, Inc. | $13.3B | $44.53 | $50.43 | +13.2% | Hold | 22.4x | 28 |
SBRASabra Health Care REIT, Inc. | $4.6B | $18.12 | $21.00 | +15.9% | Hold | 26.9x | 29 |
NHINational Health Investors, Inc. | $3.4B | $70.82 | $83.40 | +17.8% | Hold | 19.9x | 18 |
LTCLTC Properties, Inc. | $1.9B | $36.37 | $36.00 | -1.0% | Hold | 19.4x | 22 |
CTRECareTrust REIT, Inc. | $8.8B | $37.06 | $44.25 | +19.4% | Buy | 24.8x | 19 |
GMREGlobal Medical REIT Inc. | $94M | $35.74 | $40.00 | +11.9% | Buy | 595.7x | 22 |
CHCTCommunity Healthcare Trust Incorporated | $498M | $17.43 | $18.50 | +6.1% | Hold | 37.1x | 16 |
MPWMedical Properties Trust, Inc. | $3.4B | $5.65 | $11.54 | +104.2% | Hold | 49.4x | 28 |
Quick answers to the most common questions about buying VTR stock.
Ventas, Inc. (VTR) has a consensus 12-month price target of $95.86, implying 17.5% upside from $81.61. The 32 analysts covering VTR see moderate appreciation potential.
VTR has a consensus rating of "Buy" based on 32 Wall Street analysts. The rating breakdown is predominantly bullish, with 19 Buy/Strong Buy ratings. The consensus 12-month price target of $95.86 implies 17.5% upside from current levels.
At a forward P/E of 130.7853x, VTR trades at a premium valuation. The consensus price target of $95.86 (17.5% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $110 for VTR, while the most conservative target is $88. The consensus of $95.86 represents the median expectation. Our quantitative valuation model projects a bull case target of $69 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
VTR is heavily covered by Wall Street, with 32 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 19 have Buy ratings, 11 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month VTR stock forecast based on 32 Wall Street analysts shows a consensus price target of $95.86, with estimates ranging from $88 (bear case) to $110 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $52, with bear/bull scenarios of $33/$69.
Our quantitative valuation model calculates VTR's fair value at $52 (base case), with a bear case of $33 and bull case of $69. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
VTR trades at a forward P/E ratio of 130.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 151.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on VTR, with a "Buy" consensus rating and $95.86 price target (17.5% upside). 19 of 32 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
VTR analyst price targets range from $88 to $110, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $95.86 consensus represents the middle ground. Our model's $33-$69 range provides an independent fundamental perspective.
Deep dive into VTR consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.